Genscript Biotech ( (HK:1548) ) has provided an update.
Genscript Biotech Corporation announced the financial results of its associate, Legend Biotech Corporation, for the fourth quarter and year ended December 31, 2024. Legend Biotech, in which Genscript holds a 47.51% stake, filed its financial results with the SEC, highlighting recent business achievements. Shareholders are advised to consider investment risks when dealing with Genscript’s securities.
More about Genscript Biotech
Genscript Biotech Corporation, incorporated in the Cayman Islands, operates in the biotechnology industry. The company is involved in various biotech services and products, with a significant market focus on its associate, Legend Biotech Corporation, which is listed on the Nasdaq Global Selected Market.
YTD Price Performance: 13.39%
Average Trading Volume: 3,834
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.72B
For a thorough assessment of 1548 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com